Document is current
Any future updates will be listed below
-
Authors
Tykodi, Scott S https://orcid.org/0000-0002-0399-0965
Gordan, Lucio N
Alter, Robert S
Arrowsmith, Edward
Harrison, Michael R
Percent, Ivor
Singal, Rakesh
Van Veldhuizen, Peter
George, Daniel J https://orcid.org/0000-0002-0836-8542
Hutson, Thomas
Zhang, Joshua
Zoco, Jesus
Johansen, Jennifer L
Rezazadeh Kalebasty, Arash
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02982954 at ClinicalTrials.govnct02982954 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial
https://doi.org/10.1136/bmjopen-2021-058396
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0
https://doi.org/10.1136/jitc-2025-013788
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
https://doi.org/10.1136/jitc-2022-005445
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial
https://doi.org/10.1136/jitc-2021-003844
nct02982954 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial
https://doi.org/10.1136/bmjopen-2021-058396
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0
https://doi.org/10.1136/jitc-2025-013788
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
https://doi.org/10.1136/jitc-2022-005445
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial
https://doi.org/10.1136/jitc-2021-003844
nct03075423 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial
https://doi.org/10.1136/bmjopen-2021-058396
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0
https://doi.org/10.1136/jitc-2025-013788
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
https://doi.org/10.1136/jitc-2022-005445
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial
https://doi.org/10.1136/jitc-2021-003844
Documents that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0
https://doi.org/10.1136/jitc-2025-013788
Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma
https://doi.org/10.1136/jitc-2024-010958
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial
https://doi.org/10.1136/jitc-2021-003844
-
Funding
Funding for this research was provided by:
Bristol Myers Squibb
- License Information
